Background: Patient's account of personal experiences of having lived through coronavirus disease 2019 is important for understanding the magnitude of the debilitating impact of the infection. There is increasing recognition that the infection impedes multiple functional domains, but to date the evidence remains scarce. Moreover, to the author's knowledge, there are no documented cases reporting on research data derived from self-reflective first-person experience.
Case Presentation: The patient was a 59-year-old female psychologist of White self-ascribed ethnicity who had coronavirus disease 2019. She had no history of medical, neurological, or psychiatric conditions and works in a neurosurgery clinic at a large hospital as a psychologist, specializing in neuropsychology. Using the introspective method, she captured the occurrence of neuropsychological and psychological dysfunctions she experienced in the acute stage of the illness, which took place in December 2020 and lasted for 17 days. Treatment of coronavirus disease 2019 was conducted in the home environment under medical supervision and followed a standardized protocol adopted at the time in the country.
Conclusions: The data derived from the first-person experience indicated that among the most salient cognitive functions impacted by the disease were: executive control, working memory, attention, concentration, and processing speed. Furthermore, emotional instability; mood swings; racing, repetitive, or intrusive thoughts; uncontrolled associations; dizziness; fatigue; disbalance; and sleep disturbances featured consistently throughout the illness. The overall profile of these dysfunctions suggests disruption in the overall operation of the brain and particularly in the functioning of the frontal lobes. Although less tangible than the physical symptoms, the neuropsychological and psychological dysfunctions associated with coronavirus disease 2019 form a distinct cluster that has a highly debilitating impact on a person's well-being.
Download full-text PDF |
Source |
---|---|
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC8521245 | PMC |
http://dx.doi.org/10.1186/s13256-021-03104-w | DOI Listing |
Pediatr Infect Dis J
January 2025
From the Department of Medical Epidemiology and Biostatistics, Karolinska Institutet, Stockholm, Sweden.
Background: The World Health Organization classified coronavirus disease (COVID-19) as a pandemic by March 11, 2020. Children had a milder disease than adults, and many were asymptomatic. The pandemic could be seen as a natural experiment with several changes, including time spent at home.
View Article and Find Full Text PDFPLoS Med
January 2025
University of North Carolina at Chapel Hill, Chapel Hill, North Carolina, United States of America.
Background: Nirmatrelvir with ritonavir (Paxlovid) is indicated for patients with Coronavirus Disease 2019 (COVID-19) who are at risk for progression to severe disease due to the presence of one or more risk factors. Millions of treatment courses have been prescribed in the United States alone. Paxlovid was highly effective at preventing hospitalization and death in clinical trials.
View Article and Find Full Text PDFSTAR Protoc
January 2025
Guangzhou National Laboratory, Bio-Island, Guangzhou, Guangdong 510005, China; State Key Laboratory of Respiratory Disease, The First Affiliated Hospital of Guangzhou Medical University, Guangzhou, Guangdong 510182, China. Electronic address:
Binding and neutralizing antibodies are critical indicators of protection against viral pathogens and are essential for assessing the immunogenicity and efficacy of a vaccine. Here, we present a protocol comprising two assays for measuring the spike-specific binding and neutralizing antibodies in mouse plasma following severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) vaccination. We describe steps for determining binding antibody titers using enzyme-linked immunosorbent assay (ELISA) and assessing neutralizing antibody titers through a pseudovirus neutralization assay.
View Article and Find Full Text PDFAdv Sci (Weinh)
January 2025
Center for Advanced Biomolecular Recognition, Biomedical Research Division, Korea Institute of Science and Technology (KIST), Seoul, 02792, Republic of Korea.
During the COVID-19 pandemic, reverse transcription-quantitative polymerase chain reaction (RT-qPCR) has been recognized as the most reliable diagnostic tool. However, there is a need to develop multiplexed assays capable of analyzing multiple genes simultaneously to expand its application. To address this, a multiplexed RT-qPCR using a double emulsion (DE)-based carrier and a polymer microparticle reactor, termed primer-incorporated network tailored with Taqman probe (TaqPIN) is developed.
View Article and Find Full Text PDFEnter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!